Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

fulvestrant

(ful-VES-trunt)
A drug used to treat certain types of breast cancer. It is used alone or with ribociclib succinate in postmenopausal women who have not been treated with hormone therapy or whose disease got worse after treatment with hormone therapy. It is also used with palbociclib or abemaciclib in women whose disease got worse after treatment with hormone therapy. It is also being studied in the treatment of other types of cancer. Fulvestrant binds to proteins called estrogen receptors, which are found in some breast cancer cells. These proteins may cause cancer cells to grow. Fulvestrant blocks these proteins and may keep cancer cells from growing. It is a type of antiestrogen. Also called Faslodex and ICI 182780.
More Information
Search NCI's Dictionary of Cancer Terms